Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

NCT02379091 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02379091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02379091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
December 17, 2014
Completion date
December 5, 2016
Enrollment
108 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis